Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
There are currently no established safety data specifically addressing GLP-1 agonist use in active Crohn's disease, requiring thorough informed consent, close monitoring, and coordination between specialists
To date, only one clinical trial has investigated the effects of a GLP-1 agonist, exenatide, on individuals seeking treatment for AUD 11
[17] For individuals with clinically significant obesity (BMI 30 kg/m, or 27.5 kg/m in certain ethnic groups per NICE guidance), licensed pharmacological options are available through NHS pathways
It cites no manufacturer or pharmacy document for the 36-month figure, and separately notes that compounded timelines depend on the individual pharmacy's own validation studies
Because I worked in a fast-paced environment at the time, it was easy to get distracted by other tasks
Summary of Storage Timelines Key Takeaway: While all GLP-1 injectables prefer the refrigerator, they all have a safe window at room temperature
